医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Heartbeat Experts’ Dan Mintz to be Panelist at China Medical Affairs Conference in Shanghai

2013年06月14日 PM11:55
このエントリーをはてなブックマークに追加


 

SHANGHAI

Heartbeat Experts, the global leader in KOL management solutions, announced that Dan Mintz, VP Global Marketing, will participate in a panel discussion at the upcoming China Medical Affairs Summit in Shanghai on 19 June 2013. The panel will focus on market access for new pharmaceutical products in China. Topics to be addressed include payer and KOL perceptions of product value, as well as measuring KOL views on products.

Mr. Mintz is an expert in KOL management and market access with extensive experience crafting strategies for medical affairs and marketing teams in China. Heartbeat Experts has commercial offices in Shanghai, Beijing and Guangzhou supporting sales, marketing, project delivery and research.

About Heartbeat Experts:

Heartbeat Experts is the leading stakeholder management solution provider serving 20 of the top 20 pharmaceutical companies and 18 of the top 20 medical device companies. Heartbeat Experts provides software and data for KOL identification, KOL management, pricing and reimbursement, formulary access, regulatory affairs as well as a suite of stakeholder engagement products including virtual advisory boards, HCP communities and market research. With an extensive local presence, Heartbeat Experts provides these services from 25 offices worldwide.

CONTACT

Heartbeat Experts
Ben Ye, +86-21-2312-7651
Account Executive

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表